Signatera's regulatory triple, the harvest phase, and Natera's guide-raise quarter

First MRD companion diagnostic, Japan PMDA and NCCN Category 1 land in one quarter as volumes set new records — and the 90-day tape runs +72%.

NTRA · Earnings Call · 2026-08-06

One quarter, three regulatory stamps

Natera reported Q2 2026 on August 6 and the tape did not flinch — the shares are up 72% over the last 90 days and roughly 1,745% over the full history. The headline number — 1.044 million tests processed, a company record, with 283,000 clinical Signatera MRD units up 56% year-on-year and 34,000 sequentially, the largest step ever — was only part of the story. Revenue landed at $753 million, up 38% (about 40% ex Signatera ASP true-ups), at ~65% gross margins. “We had an exceptional quarter... once again exceeding 1 million units and setting a new company record with strong volume performance across the business.” — Steven Leonard Chapman, CEO · 2026-08-06 Management raised the full-year revenue guide $100 million at the midpoint to $2.85–2.91 billion — roughly 31% growth ex true-ups — while holding OpEx steady. The genuinely new element, though, is the regulatory/guideline stack. Signatera became the first MRD test to receive FDA approval as a companion diagnostic (muscle-invasive bladder cancer), the first to win Japanese PMDA approval (colorectal), and the first solid-tumor MRD test to get IVDR certification in the EU. Days later, the NCCN issued a Category 1 recommendation that explicitly describes tumor-informed multiplex-PCR MRD testing — language that uniquely maps to Signatera. That NCCN guideline is already landing in new accounts: “we are crossing the sort of tipping point in the field where doctors are really starting to believe in MRD as a core part of their practice.” — Steven Leonard Chapman, CEO · 2026-08-06

Prenatal and organ health: closing gaps, not just surfing

While oncology dominates, the quarter quietly fixed a long-standing women's-health gap. The enhanced fetal fraction Panorama test — powered by SNP-informed deep sequencing — cuts the no-call rate from ~2% to 0.5% and was validated on 3,300+ patients, including 240+ low-fetal-fraction cases. “We detected 100% of the trisomy 21 cases in that cohort.” — Solomon Moshkevich, President, Clinical Diagnostics · 2026-08-06 Management credited the launch (and Fetal Focus orders) for new-account wins that counteracted Q2's normal prenatal seasonality. Organ health also got a step-function lift: the final Medicare LCD, published July, expands surveillance frequency to 6 tests/year (kidney) and 12/year (heart/lung) in year one, with benefit starting August 30. Both are ASP-plus-volume tailwinds the guide is implicitly betting on.

From partner-driven to self-owned: the evidence engine turns

The most consequential strategic shift is quieter. Alexey walked through 70+ prospective studies accumulated since 2019, then introduced SIGNAL ER101 — Natera's first company-sponsored interventional study, an MRD-guided de-escalation of CDK4/6 inhibitors in HR+/HER2− breast cancer, a population of >200,000 annual US diagnoses where a full CDK4/6 course can cost north of $400,000.

We are just now entering the harvest phase of an investment we began 7 years ago.
Alexey Aleshin, General Manager of Oncology · 2026-08-06

The implication: Natera is moving from renting evidence (pharma and academic trials) to owning it — designing Prospective studys "to a pharma standard" across the largest histologies, which it says will compound into guidelines and reimbursement. That pivot is visible in the balance sheet. Research and development rose 63% year-on-year to $211 million, while effective net cash jumped 131% to $2.1 billion — ample runway for the ~$100 million of 2026 early-cancer-detection spend that won't generate revenue until the FIND study reads out. The FIND study, now at ~24,000 average-risk adults, is tracking toward full enrollment in Q3 2026, with a 2027 readout — the next growth wave. Prior quarters confirm the escalation. A year ago, on the Q2 2025 call, Steven bragged about new patient starts in similar superlatives: “we saw just absolute blowout record twice higher growth than we've ever seen before in new patients” — Steven Leonard Chapman, Chief Executive Officer · 2025-08-07. This quarter, the same language describes record sequential units, with new patient starts "way up." And the modeling framework is unchanged from February: CFO Mike Brophy repeated “the right way to model the growth of the Signatera units is just to take the trailing 4 quarters average for the sequential growth units” — Mike Brophy, Chief Financial Officer · 2026-02-26.

The tape and the tell

The recent tape has already voted — +72% in 90 days. The fundamentals support it: revenue compounding at 30%+ while gross margin grinds toward a 70%+ target, DSO down to 57 days with receivables-to-revenue declining, and a price-to-revenue valuation near 11.4x — rich, but not absurd, given multiple regulatory moats and a pre-revenue screening wave. The risk is symmetric: with ASPs booked at stable and upside gated to 2027, any MolDx or guideline slippage compresses the multiple. For now, this is the rare diagnostic name where volume, evidence, and the balance sheet all moved in the same direction in one quarter — and the stock is still catching up.